The automotive industry never slows down, and EV brands feel that pressure more than most. Lucid is responding to the market and to its own position by cutting 12 percent of its workforce. The move ...

Enterprises are racing to implement AI, investing heavily in model training, experimentation, and operational transformation. Yet without addressing the gravity of data at massive scale, even the most ...

Whenever you start using a service and provide your personal information, this data becomes easily accessible. Your name, phone number, address, recruitment history, and shopping habits remain in ...

Adding Merck & Co. and Moderna’s vaccine candidate to Keytruda has continued to cut the risk of cancer recurrence or death across five years of follow-up, boosting the companies’ prospects as they ...

AI storage vendor Vast Data is launching what it calls a Flash Reclamation Program to help customers in the current AI-driven memory drought. In an exclusive briefing attended by SDxCentral, Vast ...

Tuesday’s state Department of Environmental Protection hearing on “Project Gravity” was billed as an opportunity for the public to ask questions and “get educated” on the proposed data center campus ...

Einstein’s claim that the speed of light is constant has survived more than a century of scrutiny—but scientists are still daring to test it. Some theories of quantum gravity suggest light might ...

ARCHBALD — Project Gravity wants to cool nearly 2 million square feet of data centers in Archbald by tapping into Scranton’s source of drinking water. Representatives from Archbald 25 Developer LLC ...

ARCHBALD, Pa. — It's called Project Gravity, a proposal to build seven two-story data centers, each being 138,000 square feet, on a 180-plus-acre plot in Archbald. This is the first time community ...

The proposed data centers for 'Project Gravity' in Archbald have raised community concerns about their proximity to homes and potential environmental impacts. Noem calls ICE incident "domestic ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech on track to start a pivotal study next year. The Californian company’s ...